Polymorphisms in the promoter region of the CASP8 gene are not associated with non-Hodgkin's lymphoma in Chinese patients

Annals of Hematology

Volumn 90, Issue 10, 2011, Pages 1137-1144

  Xiao, Mei Sheng ^a,b   Zhang, Deng Feng ^a,c   Zeng, Yun ^d   Cheng, Yun Feng ^d   Yao, Yong Gang ^a  

^a KUNMING INSTITUTE OF ZOOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c KUNMING MEDICAL UNIVERSITY   (China)

^d ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

CASP8; Chinese; Genetic susceptibility; Non Hodgkin's lymphoma; SNP

Indexed keywords

LUCIFERASE; CASP8 PROTEIN, HUMAN; CASPASE 8; MESSENGER RNA; TUMOR PROTEIN;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; ENZYME ASSAY; FEMALE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; ONCOGENE; ONCOGENE CASPASE 8; PRIORITY JOURNAL; PROMOTER REGION; AGED; CASE CONTROL STUDY; CELL STRAIN HEK293; CHINA; COHORT ANALYSIS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HELA CELL; METABOLISM; MIDDLE AGED; REPORTER GENE; TUMOR CELL LINE;

ADULT; AGED; CASE-CONTROL STUDIES; CASPASE 8; CELL LINE, TUMOR; CHINA; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HEK293 CELLS; HELA CELLS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RNA, MESSENGER;

EID: 80055118569     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-011-1265-5     Document Type: Article

References (27)

1. Raff M (1998) Cell suicide for beginners. Nature 396:119-122 (Pubitemid 28523602)
2. Rudin CM, Thompson CB (1997) Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annu Rev Med 48:267-281 (Pubitemid 27101830)
3. Thompson CB (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267:1456-1462
4. Chen M, Wang J (2002) Initiator caspases in apoptosis signaling pathways. Apoptosis 7:313-319 (Pubitemid 34832255)
5. Nuñez G, Benedict MA, Hu Yet al (1998) Caspases: the proteases of the apoptotic pathway. Oncogene 17:3237-3245 (Pubitemid 29043976)
6. Hosgood HD 3rd, Baris D, Zhang Y et al (2008) Caspase polymorphisms and genetic susceptibility to multiple myeloma. Hematol Oncol 26:148-151
7. Andreoli V, Trecroci F, La Russa A et al (2009) CASP-9: a susceptibility locus for multiple sclerosis in Italy. J Neuroimmunol 210:100-103
8. Mandruzzato S, Brasseur F, Andry G et al (1997) A CASP- 8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 186:785-793 (Pubitemid 27381543)
9. Yeretssian G, Doiron K, Shao W et al (2009) Gender differences in expression of the human caspase-12 long variant determines susceptibility to Listeria monocytogenes infection. Proc Natl Acad Sci U S A 106:9016-9020
10. Dong LM, Brennan P, Karami S et al (2009) An analysis of growth, differentiation and apoptosis genes with risk of renal cancer. PLoS ONE 4:e4895
11. Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511 (Pubitemid 30082188)
12. Dales JP, Plumas J, Palmerini F et al (2001) Correlation between apoptosis microarray gene expression profiling and histopathological lymph node lesions. Mol Pathol 54:17-23 (Pubitemid 32128423)
13. Lan Q, Zheng T, Chanock S et al (2007) Genetic variants in caspase genes and susceptibility to non-Hodgkin lymphoma. Carcinogenesis 28:823-827 (Pubitemid 46523339)
14. Shin MS, Kim HS, Kang CS et al (2002) Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. Blood 99:4094-4099 (Pubitemid 35332052)
15. Lan Q, Morton LM, Armstrong B et al (2009) Genetic variation in caspase genes and risk of non-Hodgkin lymphoma: a pooled analysis of 3 population-based case-control studies. Blood 114:264-267
16. Soung YH, Lee JW, Kim SY et al (2004) Somatic mutations of CASP3 gene in human cancers. Hum Genet 115:112-115 (Pubitemid 39010925)
17. Bethke L, Sullivan K, Webb E et al (2008) The common D302H variant of CASP8 is associated with risk of glioma. Cancer Epidemiol Biomarkers Prev 17:987-989 (Pubitemid 351536434)
18. Cox A, Dunning AM, Garcia-Closas M et al (2007) A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet 39:352-358 (Pubitemid 46328496)
19. MacPherson G, Healey CS, Teare MD et al (2004) Association of a common variant of the CASP8 gene with reduced risk of breast cancer. J Natl Cancer Inst 96:1866-1869 (Pubitemid 40081324)
20. Son J-W, Kang H-K, Chae MH et al (2006) Polymorphisms in the caspase-8 gene and the risk of lung cancer. Cancer Genet Cytogenet 169:121-127 (Pubitemid 44287103)
21. Sun T, Gao Y, Tan W et al (2007) A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 39:605-613 (Pubitemid 46676113)
22. Frank B, Rigas SH, Bermejo JL et al (2008) The CASP8-652 6N del promoter polymorphism and breast cancer risk: a multicenter study. Breast Cancer Res Treat 111:139-144 (Pubitemid 352009221)
23. Haiman CA, Garcia RR, Kolonel LN et al (2008) A promoter polymorphism in the CASP8 gene is not associated with cancer risk. Nat Genet 40:259-260, author reply 260-261
24. Zou Y, Zeng Y, Zhang DF et al (2010) IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Biochem Biophys Res Commun 402:378-383
25. Stephens M, Donnelly P (2003) A comparison of Bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73:1162-1169 (Pubitemid 37414228)
26. Wang M, Zhang Z, Tian Y et al (2009) A six-nucleotide insertiondeletion polymorphism in the CASP8 promoter associated with risk and progression of bladder cancer. Clin Cancer Res 15:2567-2572
27. Ni C, Ye Y, Wang M et al (2009) A six-nucleotide insertiondeletion polymorphism in the CASP8 promoter is associated with risk of coal workers' pneumoconiosis. J Toxicol Environ Health A 72:712-716